Biomarkers in Cancer Detection and Monitoring of Therapeutics

Volume 1: Discovery and Technologies

1st Edition - November 16, 2023
Editors: Ranbir Chander Sobti, Awtar Krishan, Aastha Sobti
Language: English
Paperback ISBN:
9 7 8 - 0 - 3 2 3 - 9 5 1 1 6 - 6
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 5 1 1 7 - 3

Biomarkers in Cancer Detection and Monitoring of Therapeutics, Volume One, Discovery and Technologies discusses how molecular biomarkers are used to determine predis… Read more

Purchase options

Limited Offer

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

Biomarkers in Cancer Detection and Monitoring of Therapeutics, Volume One, Discovery and Technologies discusses how molecular biomarkers are used to determine predisposition, facilitate detection, improve treatment and offer prevention guidelines for different cancer types. This first volume in the series focuses on techniques and approaches recently developed to assist in the decision of which biomarker to use for specific conditions. Topics covered include circulating tumor cells and circulating tumor DNA, exomes, tumor microenvironment, gene editing, artificial intelligence and robotics. In addition, the book discusses the development and applications of organoids and precision medicine.This book will be a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of biomarkers in cancer research.

Cover image
Title page
Table of Contents
Copyright
Contributors
Preface
Chapter One Milestones in cancer research
Abstract
1 Introduction
2 Landmark researches
3 Summary
References
Chapter Two Cancer burden: Epidemiology, racial, and geographical disparities
Abstract
1 Introduction
2 Global burden of cancer
3 Social class disparities in cancer
4 Racial disparities in cancer
5 Risk factors for cancer
6 Reasons for disparities in cancer
7 Response to the burden of cancer
8 Conclusion
References
Chapter Three Technological evolution in cancer diagnosis and therapeutics
Abstract
1 Introduction
2 Cancer diagnosis
3 Cancer therapy
4 Conclusion
References
Chapter Four How does time speak about cancer, its diagnosis, treatments, and challenges?
Abstract
Acknowledgment
1 Introduction
2 What causes cancer?
3 New knowledge about cause of cancer
4 Animal models and chemical carcinogenesis
5 History of cancer treatment
6 Major breakthroughs in cancer research
7 Cancer in India since antiquity
8 Conclusion
References
Chapter Five Role of artificial intelligence in cancer diagnostics and therapeutics
Abstract
1 Introduction
2 Artificial intelligence in cancer diagnostics
3 Artificial intelligence in cancer drug therapy
4 Limitations to artificial intelligence in cancer diagnostics and therapeutics
5 Future prospective of artificial intelligence in cancer management
References
Chapter Six Addressing the diagnosis and therapeutics of malignant tumor cells
Abstract
Acknowledgment
1 Introduction
2 Tumor-related factors; tumor stage at diagnosis
3 Tumor subtype and location
4 Prior consultations and usage of health-care services
5 Preceding symptomatic presentations
6 Health-care factors
7 Patient factors
8 Age of the patient
9 Breast cancer
10 Lung cancer
11 Prostate cancer
12 Ovarian cancer
13 Other cancers
14 Biomarkers; imaging technique
15 Nanomedicine
16 Extracellular vesicles (EV) for cancer diagnosis and therapy
17 Natural antioxidants in cancer therapy
18 Targeted therapy and immunotherapy
19 Gene therapy for cancer treatment
20 Conclusion
References
Chapter Seven Insights into genetic predisposition of somatic cancers
Abstract
1 Introduction
2 Germline cancers
3 Somatic cancers
4 Identifying somatic mutations
5 Next-generation sequencing (NGS) in mutation detection
References
Chapter Eight The use of tumor markers in prognosis of cancer and strategies to prevent cancer predisposition and progress
Abstract
1 Introduction
2 The use of tumor markers in prognosis of cancer
3 Strategies to prevent cancer predisposition and progress
4 Conclusions and recommendations
References
Further reading
Chapter Nine Cytogenetics to multiomics in biology of cancer
Abstract
1 Introduction
2 Karyotyping
3 Recent advances
4 Conclusion
References
Chapter Ten Role of noncoding RNA as biomarkers for cancer
Abstract
1 Introduction
2 Micro RNA
3 Amplification or deletion of miRNA genes
4 Dysregulated epigenetic changes
5 Defects in miRNA biogenesis machinery
6 Long noncoding RNAs
7 Regulatory functions of housekeeping ncRNAs
8 LncRNA modes of action in the nucleus
9 Characteristics and functions of long noncoding RNAs
10 ncRNAs in clinical practice
References
Further reading
Chapter Eleven Viral miRNAs role as diagnostic, prognostic biomarkers for cancer and infectious diseases
Abstract
1 Introduction
2 Prospects of viral microRNA as potential biomarkers in cancer
3 Antiapoptotic viral miRNAs
4 Viral miRNAs in tumor progression
5 Prospects of viral microRNAs as potential biomarkers in infectious diseases
6 Viral miRNA detection platforms
7 Advantages of viral miRNAs as biomarkers
8 Future challenges
References
Chapter Twelve Pharmacogenomics and oncology: A therapeutic approach for cancer treatment
Abstract
Conflict of interest
1 Introduction
2 Targeting biomarkers in cancer therapy
3 Conclusion
References
Chapter Thirteen Obesity: Emerging risk factor for cancer beyond metabolic syndrome
Abstract
1 Introduction
2 Epidemiologic evidences supporting the link between obesity and cancer
3 Effect of weight gain and weight loss paradigm in regulating cancer risk
4 Pathophysiology of obesity mediated cancer
5 Prevention and treatment
6 Conclusion
References
Chapter Fourteen Homologous repair deficiency and PARP inhibitors in cancer management
Abstract
Acknowledgment
1 DNA damage and repair
2 Homologous recombination deficiency
3 Biomarkers to evaluate HRD status
4 PARP inhibitors
5 Future perspectives
References
Chapter Fifteen Molecular prospects of transcription activator-like effector nucleases (TALENs) in cancer management: Challenges and adaptations
Abstract
1 Introduction
2 Emergence and principles of technique
3 TALENs in cancer management
4 Executing challenges, limitations, and adaptations in TALENs
5 Concluding remarks
6 Future prospects
References
Chapter Sixteen Immunopeptidomic approaches for management of cancer
Abstract
1 Introduction to immunopeptidomics
2 Identification of peptide-HLA antigen
3 Translating immunopeptidomics to immunotherapy
References
Chapter Seventeen Regulation of tumor microenvironment by nutrient trafficking
Abstract
1 Introduction
2 TME and changes in tumor cells metabolism
3 Nutrients and cancer cell metabolism
4 Strategies adopted by cancer cells to alter the tumor microenvironment via metabolic reprogramming
5 Cancer metabolism based therapies
6 Conclusion and future directions
References
Chapter Eighteen Environmental factors influencing epigenetic changes initiating neoplastic changes
Abstract
1 Introduction
2 Epigenetic mechanisms influencing gene expression
3 Environmental influences on epigenetic changes
4 Chemically influenced epigenetic changes
5 Trichloroacetic acid (TCA), trichloroethylene (TCE), and dichloroacetic acid (DCA)
6 Reproductive toxicants and chemicals disrupting endocrine mechanisms
7 Epigenetic drugs
8 DNMT inhibitors
9 HDAC inhibitors
10 Innovative epigenetic targets as research hotspots
11 Combination of epigenetic drugs with other treatment options for cancer
12 Conclusion and future perspectives
References
Chapter Nineteen Somatic mutation: Pharmacogenomics in oncology care
Abstract
1 Introduction
2 Cancer pharmacogenomics
3 Somatic mutation
4 Biomarkers
5 Future direction
6 Conclusion
References
Chapter Twenty Precision medicine: Dose for anticancer therapy
Abstract
1 Introduction
2 Pathophysiology of cancer
3 Pharmacogenetics in cancer
4 Types of enzymes and transporters responsible for pharmacokinetics of anticancer drugs
5 Future perspectives
6 Concluding remarks
References
Index

Ranbir Chander Sobti

Professor Sobti is an Education Consultant Governor of Bihar and Senior Scientist at the Indian National Science Academy, in addition to Former Vice Chancellor at Babasaheb Bhimrao Ambedkar University, Lucknow, and Panjab University, Chandigarh, India. Beginning his career as a Cytogeneticist, Professor Sobti moved on to explore the role of gene polymorphisms and their expression in the genesis of various cancers, COPD, AIDS and metabolic syndrome. He has identified disease susceptible / protective novel genotypes and determined the crucial role of SACS-1 and STAT genes in the genesis of cervical and prostate cancers. He has contributed to 270 research publications, 35 books and 23 sponsored research projects. He has received prestigious awards and medals, including the honor of “Padma Shri” from the Government of India for his contribution to higher education. Additionally he was honored with ‘Bharat Gaurav’, Lifetime Achievement Award at the House of Commons, British Parliament, London, UK.

Affiliations and expertise

Senior Scientist and Professor Emeritus, Department of Biotechnology, Panjab University, Chandigarh, India

Awtar Krishan

Dr. Awtar Krishan PhD is a world-renowned scientist. He obtained his PhD from Panjab University (1962) and the Univ. of Western Ontario, Canada (1963) in Cytogenetics and Anatomy. From 1965 to 1977, he was at the Sidney Farber Cancer Institute, Harvard Medical School as Head of the Tissue Ultrastructure and Experimental Pathology Labs. He has developed flow cytometric techniques for rapid analysis of DNA content by hypotonic propidium iodide, monitoring of drug retention and resistance, and more recently for monitoring hormone receptor expression in archival tumors. He is currently Director, Analytical Cytometry Laboratory, at University of Miami.

Affiliations and expertise

Professor, Sylvester Comprehensive Cancer Center, University of Miami Health System, USA

Aastha Sobti

Aastha Sobti is a Doctoral student at the Department of Immunotechnology at Lund University, Sweden. Her research areas interests include translational medicine, clinical dentistry, cancer immunology, biomarkers, diagnostics and medical oncology.

Affiliations and expertise

Doctoral student, Department of Immunotechnology, Lund University, Lund, Sweden

Life sciences

Physical sciences & Engineering

Social sciences & Humanities

Health

Biomarkers in Cancer Detection and Monitoring of Therapeutics

Volume 1: Discovery and Technologies

Purchase options

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Ranbir Chander Sobti

Awtar Krishan

Aastha Sobti